Trials / Completed
CompletedNCT01922089
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 498 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LCZ696 | LCZ696 50 mg/100 mg/200 mg bid |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-08-14
- Last updated
- 2015-10-15
- Results posted
- 2015-10-15
Locations
105 sites across 11 countries: United States, Bulgaria, Finland, Germany, Hungary, Italy, Puerto Rico, Slovakia, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01922089. Inclusion in this directory is not an endorsement.